Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread. Therefore, we want to find out whether taking cabozantinib after treatment with surgery and chemotherapy is effective and safe for patients who responded or had stable disease after their chemotherapy. All participants will receive 4-6 cycles of standard chemotherapy. Those with stabilization or response to the standard chemotherapy will be split into 2 groups (cabozantinib or placebo).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01979393
Study type Interventional
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 2015
Completion date May 2024

See also
  Status Clinical Trial Phase
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Recruiting NCT00162721 - The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Phase 3
Completed NCT01806350 - Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors N/A
Recruiting NCT05881967 - Molecular Mechanism Study of Uterine Sarcoma
Active, not recruiting NCT06244251 - Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids N/A
Completed NCT00020267 - Vaccine Therapy in Treating Patients With Metastatic Cancer Phase 1
Recruiting NCT04224467 - The Application of Real-Time Near-infrared Imaging in Gynecological Surgery N/A
Completed NCT01303094 - Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma Phase 2
Available NCT03493165 - Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)